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Abstract
Background: The Ras association domain family 1 (RASSF1) gene is a Ras effector encoding two major mRNA
forms, RASSF1A and RASSF1C, derived by alternative promoter selection and alternative mRNA splicing. RASSF1A is
a tumor suppressor gene. However, very little is known about the function of RASSF1C both in normal and
transformed cells.
Methods: Gene silencing and over-expression techniques were used to modulate RASSF1C expression in human
breast cancer cells. Affymetrix-microarray analysis was performed using T47D cells over-expressing RASSF1C to
identify RASSF1C target genes. RT-PCR and western blot techniques were used to validate target gene expression.
Cell invasion and apoptosis assays were also performed.
Results: In this article, we report the effects of altering RASSF1C expression in human breast cancer cells. We
found that silencing RASSF1C mRNA in breast cancer cell lines (MDA-MB231 and T47D) caused a small but
significant decrease in cell proliferation. Conversely, inducible over-expression of RASSF1C in breast cancer cells
(MDA-MB231 and T47D) resulted in a small increase in cell proliferation. We also report on the identification of
novel RASSF1C target genes. RASSF1C down-regulates several pro-apoptotic and tumor suppressor genes and up-
regulates several growth promoting genes in breast cancer cells. We further show that down-regulation of caspase
3 via overexpression of RASSF1C reduces breast cancer cells’ sensitivity to the apoptosis inducing agent, etoposide.
Furthermore, we found that RASSF1C over-expression enhances T47D cell invasion/migration in vitro.
Conclusion: Together, our findings suggest that RASSF1C, unlike RASSF1A, is not a tumor suppressor, but instead
may play a role in stimulating metastasis and survival in breast cancer cells.
Background
The Ras association domain family 1 (RASSF1) proteins
are postulated to function as Ras effectors and to affect
cell growth. The RASSF1 gene resides on chromosome
3p21.3, a region that often undergoes homozygous or
heterozygous deletions and hypermethylation-induced
suppression in many human cancers [1,2]. The RASSF1
gene encodes multiple isoforms derived by alternative
promoter selection and alternative mRNA splicing [1,2],
with two major isoforms called RASSF1A and RASSF1C.
The RASSFIA protein (340 amino acids) contains an
amino-terminal diacyl glycerol binding domain (C1
domain), an ataxia telangiectasia mutated (ATM) phos-
phorylation site, and a carboxy-terminal putative Ras
association (RA) domain. The RASSFIC protein (270
amino acids) contains the ATM phosphorylation site
and the RA domain, but not the C1 domain [1,2].
RASSF1A is a tumor suppressor gene which is epigen-
etically inactivated by cytidine methylation in many
human solid tumors. It has been reported that in 80 to
100% of lung cancer cell lines and tumors [1-4], 49 to
62% of breast cancers [3,5], 67 to 70% of nasopharyngeal
cancers [6], 90% of hepatocellular carcinomas [7], 91%
of renal cell carcinomas [8], and 70% of prostate cancers
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inactivated. In addition, RASSF1A over-expression
reduces colony formation, suppresses anchorage inde-
pendent growth, inhibits tumor growth in nude mice,
and inhibits cell growth by inducing G1-S phase cell
cycle arrest and by blocking cyclin D accumulation
[2,8,11,12]. Studies of RASSF1A knockout mice showed
that RASSF1A -/- and RASSF1A+/- mice exhibit
enhanced tumor multiplicity and tumor size compared
to wild type animals upon exposure to the chemical car-
cinogens benzo(a) pyrene and urethane [13].
The RASSF1C isoform differs from the RASSF1A iso-
form by having a distinct N-terminus and lacking the
diacyl glycerol binding domain. Unlike RASSF1A,
RASSF1C has not been extensively studied, and very lit-
tle is known about its role in cell growth, survival, and
metastasis. In contrast to RASSF1A, RASSF1C is
expressed in almost all human solid tumors. The major-
ity of published literature indicates that RASSF1C has
no tumor-suppressor activity [2,9,11,12,14]. However,
some reports suggest that RASSF1C may function as a
tumor suppressor in ovarian, prostate, renal cancer cells
[15-17]. We have recently identified RASSF1C as an
Insulin-like Growth Factor Binding Protein-5 (IGFBP-5)
interacting protein and have shown that silencing of
RASSF1C expression resulted in a significant decrease in
osteosarcoma and lung cancer cell proliferation [18,19].
We have also shown that over-expression of RASSF1C
increased cell proliferation of the lung cancer cell line
NCI H1299, suggesting a growth promoting role for
RASSF1C in lung cancer cells [19]. In this paper we
report on the effects of silencing and over-expressing
RASSF1C on human breast cancer cell growth, apopto-
sis, and invasion, and on the identification of novel
RASSF1C target genes.
Methods
Cell culture
The human breast cancer cell lines Hs578T, MDA-
MB231 and T47D were obtained from American Type
Culture Collection ATCC, Manassas, VA). Cell culture
was carried out as recommended by ATCC. Hs578T
and MDA-MB231 cells were grown in DMEM supple-
mented with 10% calf bovine serum. T47D cells were
grown in RPMI-1640 medium supplemented with 10%
calf bovine serum and 0.2 units/mL insulin. The human
mammary epithelial cell line AG1132B was obtained
from Coriell Institute for Medical Research (Camden,
NJ). Cell culture was carried out as recommended by
the supplier.
Transfection of cell lines with plasmid DNA
The MDA-MB231 and T47D cell lines were transfected
with siRNA-RASSF1C and control plasmids as previously
described [20]. Since the shRNA plasmids used in this
study would target both RASSF1A and RASSF1C
mRNAs, we utilized breast cancer cells that express
RASSF1C but not RASSF1A. Cells were plated at 20,000
and 50,000 cells per well in the appropriate medium with
10% calf serum in 24 and 6 well culture dishes, respec-
tively. After 24 hr, the cells were transfected with 1 μg/
ml plasmid DNA using Lipofectamine (Invitrogen, Carls-
bad, CA) using recommended conditions. 48 hr post-
transfection, cells were collected and were used for RNA
extraction. 200 ng of total RNA was used to prepare
cDNA with the Omniscript kit (Qiagen, Valencia, CA).
100 ng of the reverse transcriptase reaction was used for
PCR using the HotStart master mix (Qiagen, Valencia,
CA) and PCR reactions were run with the following con-
ditions: 95°C 1 min, 60°C for 30 sec, and 72°C for 30 sec
for 35 cycles.
Alamar blue assay
Cells were treated with either siRNA-RASSF1C (sup-
presses RASSF1C expression) or control plasmid for
48 hr, and cell proliferation was measured by the alamar
blue assay as previously described [18,19].
3H-Thymidine incorporation
MDA-MB231, T47D, and AG1132B cells were treated
with either siRNA-RASSF1C (suppresses RASSF1C
expression) or control plasmid for 18 hr. 3H-thymidine
was then added and cells were labeled for 6 hr before
cultures were terminated and 3H-thymidine incorpora-
tion was assayed as previously described [19].
Construction of a tet-inducible expression system that
expresses RASSF1C
In order to over-express RASSF1C cDNA in human
breast cancer cells in a regulated fashion, we chose to use
a doxycycline (dox)-inducible Murine Leukemia Virus
based retroviral vector that was developed in house
(Chen et. al., manuscript in preparation). Using the YFP-
RASSF1C plasmid [18,19] as a template, the full-length
HA-RASSF1C coding sequence was cloned using the for-
ward primer: 5′ GGG TCG ACG CGG CCG CC ATG-
TACCCATACGATGTTCCGGATTACGCT GGC GAG
GCTGAAACACCTT 3′ and the reverse primer: 5′ CGG
GAT CC TCA CCC AAG GGG GCA GGC GTG CAG
3′, and the HA-IGFBP-5 coding sequence was cloned
using the forward primer: 5′ GGG TCG ACG CGG CCG
CC ATGTACCCATACGATGTTCCGGATTACGCT
GGC TCC TTC GTG CAC TGC GA 3′,a n dt h er e v e r s e
primer: 5′ CGG GAT CC TCA CTC AAC GTT GCT
GCT GTC GAA 3′ flanked by NotI and BamHI restric-
tion enzyme sites, respectively. The NotI and BamHI
sites in the pGYT plasmid were used to insert the
RASSF1C cDNA sequence down stream of the TetO and
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orientation were confirmed by sequencing the pGYT-
HA-RASSF1C plasmid. This plasmid then was used to
produce VSV-G pseudotyped MLV-based vector as
described [20].
MDA-MB231 and T47D breast cancer cell lines were
seeded at 1 × 10
5 cells/well in 6-well plates. After 24 hr
of incubation, the cells were transduced with MLV-
based vectors rtTA-GYT (vector without transgene),
rtTA-GYT-GFP, and rtTA-GYT-HA-RASSF1C with dif-
ferent MOI in 6-well plates, using 2 or 3 serial infection
cycles as described [20]. After 1-4 days, cells were trea-
t e dw i t hu pt o1×1 0
-6 M doxycycline (dox) for 48 hr.
HA-RASSF1C expression was assessed by Western blot
analysis using anti-HA antibody. We tested the MLV-
GFP vector expression in human breast cancer cell lines
and demonstrated that a 10 fold induction of GFP
expression can be achieved with a dox concentration of
1 ug/ml.
RNA isolation and RT-PCR analysis
Total RNA from human cell lines was isolated from
confluent cultures using the Absolutely RNA Microprep
K i t( S t r a t a g e n e ,L aJ o l l a ,C A ) .1μg of total RNA was
used to set up reverse transcriptase (RT) reactions using
the superscript kit (Qiagen, Valencia, CA) and the RT
reactions were subsequently used to set up real-time
PCR reactions using 1 μl of RT as a template. 1 μgo f
total RNA was used to perform reverse transcription
reactions (RTs) and 1 ul of the RT reaction was used to
set up qRT-PCR reactions in triplicates using RASSF1A
and RASSF1C specific primer. RASSF1A forward primer
is 5′GGCGTCGTGCGCAAAGGCC and RASFF1C for-
ward primer: is 5′CTGCAGCCAAGAGGACTCGG 3′,
and the reverse primer for both RASSF1A and 1C is 5′
GGGTGGCTTCTTGCTGGAGGG 3′ [2]. The real-time
PCR reactions were set up using SYBR green PCR mas-
ter mix (Bio-Rad, Hercules, CA) and the PCR reactions
were run using the Opticon 2 PCR machine (Bio-Rad).
The PCR reactions were run using the following proto-
col: 1. incubate at 95°C for 10 min, 2. incubate at 95°C
for 15 sec, 3. incubate at 60°C for 30 sec, 4. incubate at
7 2 ° Cf o r3 0s e c ,5 .g ot os t e p2f o r3 9m o r ec y c l e s ,6 .
melting curve from 60°C to 95°C, read every 1.0°C.
Western blot analysis
Western blot analysis was carried out using the Odys-
sey® Infrared System (LI-COR Biosciences, Lincoln, NE).
Anti-caspase 3, P-ERK1/2, total ERK1/2, and -GHR anti-
bodies were purchased from Santa Cruz Biotechnology
(1: 250-1000, Santa Cruz, CA), the anti-HA antibody
was purchased from Covance (1:1000; Berkeley, CA), the
anti-CXCR4 antibody was purchase from Millipore
(1:500; Temecula, CA), and the anti-trans glutaminase 2
(1:1000; TGM2) antibody was purchased from Sigma
(Saint Luis, MO). Fluorescently labeled secondary anti-
bodies were purchased from LI-COR Biosciences
(1:5000). Cells were collected and lysed in RIPA buffer
supplemented with protease inhibitors. 30-40 ug of pro-
tein was separated on 12% SDS-PAGE gels and trans-
ferred to nitrocellulose membranes. The membranes
w e r eb l o c k e do v e r n i g h ta t4 ° Ci nT B S Ta n dd r i e dm i l k .
Incubation with antibodies was carried out in Odyssey®
Infrared System blocking buffer (diluted 1:10 in PBST
blocking buffer).
Microarray analysis
Hybridization of 12 μg of labeled cRNA to an Affyme-
trix U133 plus 2.0 chip was carried out in triplicates and
data analyses were carried out at the UCLA Microarray
facility core, Department of Pathology. The control sam-
ple is RNA from T47D cells stably transduced with
MLV-backbone (T47D-BB) and the experimental sample
is RNA from T47D cells stably transduced with MLV-
RASSF1C (T47D-1C). Prior to RNA isolation, T47D-BB
and T47D-1C cells were treated with 1 μg/ml doxycy-
cline for 48 hr. Data analysis was performed using
dChip [21]. Thresholds for selecting significant genes
were set at a relative difference > = 1.5-fold (or/and 2-
fold), absolute signal difference > = 50, and p < 0.05.
Genes that met all three criteria were considered as sig-
nificant changes. Comparison results with False Discov-
ery Rate (FDR) <5% was considered as a valid analysis.
The microarray data has been deposited in the Gene
Expression Omnibus (GEO) data base and the accession
number is GSE24473.
Primers used to validate selected RASSF1C target genes
Caspase 3 gene primers were purchased from realtimepri-
mers.com (Elkins Park, PA). Other gene primers were as
follows: Cyclophilin forward primer 5′ GCATA-
CAGGTCCTGGCATCT3 and reverse 5′TCTTGCTGGT
CTTGCCATTC3′;C R E Gf o r w a r dp r i m e r :5 ′GTGCCC
TATTTCTACCTGAGCC 3′ and reverse primer 5′AGC
ATTATGTGAACACAAAGGGG 3′; CXCR4 forward pri-
mer: ATGAAGGAACCCTGTTTCCGT and reverse pri-
mer 5′ AGATGATGGAGTAGATGGTGGG 3′;E G R 1
forward primer: 5′ATGAAGGAACCCTGTTTCCGT 3′
and reverse primer 5′ ATGATGGAGTAGATGGTGGG
3′; GHR forward primer 5′ GCTGCTGTTGACCTTGGC
3′ and reverse primer 5′ACCTCATCTGTCCAGTGG 3′;
MRAS forward primer: 5′TTTGTGCCTGACTATGA
CCCC 3′ and reverse primer 5′ TGACGGAGTAGAC-
GATGAGGA 3′;a n dH O X A 1f o r w a r dp r i m e r :5 ′ CGCC
TCAATACATTCACCACT 3′, and reverse primer 5′
CCAGCAGGACTGACCTGTTTT 3′.T h eR T - P C R
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was calculated using the 2
-ΔΔC
T method [22].
Infection of breast cancer cells with Mission® lentiviral
shRNA tranduction particles
Breast cancer cells were plated at 5000/well in 96-well
plates 24 hrs before infection.
Cells were incubated with 8 μg/ml hexadimethrine
bromide for two hours before virus particles were
added. Cells were infected with Mission® non-target
shRNA control transduction particles or with multiple
Mission® lentiviral shRNA transduction particles (NMID:
NM_007182) for silencing RASSF1C (Sigma, St. Louis,
MO). Since the lentiviral shRNA Transduction Particles
(NMID: NM_007182) used in this study would target
both RASSF1A and RASSF1C, we used breast cancer
cells that express RASSF1C but not RASSF1A. The
infections were carried outu s i n ga nM O Io fa ta so u t -
line in the supplier manual. Infected cells were selected
in media containing 2 μg/ml puromycin for 2-4 weeks
and then cells were harvested. Knockdown validation of
RASSF1C expression was assessed by qRT-PCR using
RASSF1C specific primers.
Caspase 3 activity assay
Caspase 3 activity was assayed using the Apo3/7 caspase
activity assay (Promega, Madison, WI). Cells were plated
in 96-well plates at 5000 cells/well and the next day
cells were treated with doxycycline, DMSO, etoposide at
45 umol/ml, or doxycycline and etoposide for 48 hr
before cells were assayed for caspase 3 activity. Etopo-
side was purchased from Sigma and diluted in DMSO
(Sigma) to a concentration of 45 mM and doxycycline
was purchased from Invitrogen (Carlsbad, CA).
DNA fragmentation assay
Breast cancer cells stably over-expressing RASSF1C were
incubated for 14 days in presence of 1 μg/ml doxycy-
cline before cells were used to isolate genomic DNA for
DNA fragmentation analysis using an Apoptotic DNA
Ladder Kit (Roche Applied Science, Mannheim, Ger-
many). Apoptotic DNA ladder corresponding to geno-
mic DNA isolated from lyophilized apoptotic U937 cells
that were treated with 4 ug/ml camptothecin for 3 hrs
that were provided with the kit used as a positive con-
trol for apoptosis.
In vitro cell invasion assay
The 24-well plate BD BioCoat™ Matrigel™ Invasion
Chamber (BD Biosciences. Bedfor, MA) was used to
co-culture T47D breast cancer cells with human stro-
mal cells, Hs27a according to the user manual. The
Hs27a cells were seeded at 25,000 cells per well in the
24-well BD Falcon™ TC Companian Plate in DMEM
supplemented with 10% calf bovine serum. T47D cells
were seeded at a density of 25,000 cells in the Matrigel
chambers, T47D-BB and T47D-1C were grown in
RPMI-1640 medium supplemented with 10% calf
bovine serum and 0.2 units/mL insulin. Then the
chambers containing the T47D-BB and T47D-1C were
transferred to the well containing the Hs27a stromal
cells and incubated for 22 hours. MDA-MB231 and
T47D cells were also seeded at a density of 25,000 cells
in the Matrigel chambers and the chambers were trans-
ferred to wells containing either 40 ng/ml SDF-1 con-
ditioned medium or control medium lacking SDF-1
and incubated for 22 hours. The cells in the lower sur-
face of the membrane were fixed methanol and stained
with 1% Toluidine blue per the user manual instruc-
tions. The stained membranes were photographed
through the microscope and invading cells were
counted.
Statistics
Data are presented as mean values ± SEM and analyzed
with Student’s t-test. Values ≤0.05 were considered
significant.
Results
Silencing of RASSF1C decreases breast cancer cell
proliferation
Because RASSF1C and RASSF1A are structurally similar,
but appear to have opposing effects, it is possible that
they may interact and modulate each other’s effects.
Therefore, prior to silencing RASSF1C mRNA, the
endogenous RASSF1A and RASSF1C mRNA levels were
measured in MDA-MB231 and T47D breast cancer
cells. RASSF1C is readily detectable, while RASSF1A is
barely detectable in both cell lines (Figure 1A).
Next, expression of RASSF1C was silenced with small
interfering RNA (siRNA) technology. The siRNA-
RASSF1C plasmid used in this study is one of three
RASSF1C siRNA plasmids [18] that we previously demon-
strated to consistently reduce HA-RASSF1C protein
expression compared to non-target siRNA oligos as judged
by Western blot analysis using anti-HA antibody [19].
Cells transfected with siRNA-RASSF1C plasmid
showed a significant decrease (p < 0.05) in cell prolifera-
tion compared to cells transfected with control plasmid
as judged by the alamar blue and the
3H-thymidine
incorporation assays (Figure 1B and 1C). To confirm
that the inhibitory effect of RASSF1C siRNA on cell
number correlated with reduction of RASSF1C mRNA,
RASSF1C mRNA levels were measured in MDA-MB231
and T47D cultures treated with siRNA-RASSF1C or
control plasmid. Figure 1D shows that transient trans-
fection with siRNA-RASSF1C reduced RASSF1C mRNA
levels in these breast cancer cells. We have also
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Page 4 of 14Figure 1 (A) RT-PCR analysis of RASSF1A and RASSF1C expression in breast cancer cell lines (MDA-MB231 and T47D) using RASSF1A
and RASSF1C specific primers. The RT-PCR results clearly show that RASSF1C mRNA is expressed in both cell lines. Unlike RASSF1C,
RASSF1A mRNA expression was not readily detected in MDA-MB23 and T47D cells. RASSF1A and RASSF1C cDNAs were used as templates as
control for RASSF1A (1A-cont) and RASSF1C (1C-cont) primers and actin was used as an internal control. (B) MDA-MB231 and T47D breast cancer
cells were transfected with psilencer-RASSF1C-258 (siRNA-1C) to silence RASSF1C and pSilencer (control) plasmids as previously described [18,19].
The proliferation of cells treated with siRNA-1C was significantly reduced (P < 0.05, t-test) compared to cells transfected with the empty
pSilencer plasmid. (C) Transfected MDA-MB231 and T47D cells were also incubated with 3H-thymidine and 3H-thymidine incorporation was
assayed as previously described [19]. Proliferation of cells treated with siRNA-1C was significantly reduced (P < 0.05 vs vector control, t-test)
compared to cells transfected with control plasmid. Values are mean ± SEM of 8 replicas; experiments were performed at least three
independent times. (D) RT-PCR analysis of RASSF1C expression in transfected MDA-MB231 and T47D either transfected with psilencer-RASSF1C-
258 (siRNA-1C) or pSilencer plasmid alone (control). The RT-PCR results clearly show that RASSF1C mRNA was significantly reduced in cells
treated with siRNA-1C compared to control. The amplification of actin as an internal control is the same in both treated and control cells. (E)
T47D breast cancer cells were infected with Mission® lentiviral-shRNA-control particles (lentiviral-control) and Mission® lentiviral-shRNA-RASSF1C
(lentiviral-shRNA-1C) to silence RASSF1C. The proliferation of cells infected with lentiviral-shRNA-1C was significantly reduced (P < 0.001, t-test)
compared to cells infected with lentiviral-shRNA-control.
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lentiviral shRNA transduction particles to silence
RASSF1C expression in T47D cells (Figure 1E). These
findings suggest that RASSF1C appears to be important
in promoting breast cancer cell growth.
Over-expression of RASSF1C in breast cancer cells does
not inhibit breast cancer cell growth
To further elucidate the function of RASSF1C and
demonstrate that RASSF1C is not a tumor suppressor,
we carried out RASSF1C over-expression studies in
breast cancer cells using a tet-inducible Mouse Leuke-
mia Virus-based retroviral vector to express HA-tagged
RASSF1C fusion protein. Cells were stably transduced
with MLV-backbone (BB) orM L V - R A S S F 1 C( 1 C )a s
outlined in Materials and Methods. Western blot analy-
sis using an anti-HA-tag antibody to detect the HA-
RASSF1C fusion protein verified that RASSF1C was
over-expressed in cells transduced with the MLV-
RASSF1C vector following treatment with 1 μg/ml doxy-
cycline for 48 hr (Figure 2A). Over-expression of
RASSF1C did not inhibit cell proliferation. Instead, it
consistently resulted in a small but reproducibly and sta-
tistically significant increase in cell proliferation of
Hs578T, MDA-MB231, and T47D cells stably transduced
with MLV-HA-RASSF1C (1C) compared to an empty
MLV-backbone (BB) as demonstrated by
3H-thymidine
cell proliferation assays (Figure 2B and 2C). These find-
ings demonstrate that RASSF1 C over-expression does
not inhibit breast cancer cell growth and may suggest a
potential role of RASSF1C in promoting cancer cell
growth and progression.
Assessment of RASSF1C expression in primary mammary
epithelial cells and breast cancer cell lines
We assessed the expression of RASSF1A and RASSF1C
in primary mammary epithelial (AG1132B) cells and
established breast cancer cell lines using quantitative
real time PCR (qRT-PCR). The RT-PCR reactions were
carried out in triplicates and the fold change was
calculated using the 2
-ΔΔC
T method [22]. Interestingly,
RASSF1C expression was at least 6 fold higher and
RASSF1A was at least 2.5 fold lower in the breast cancer
cell lines (Hs578T, MDA-MB231, and T47D) compared
to the normal mammary epithelial cells, AG1132B)
(Table 1). The elevated expression of RASSF1C detected
in established breast cancer cell lines compared to pri-
mary cells is indeed consistent with our hypothesis that
RASSF1C, unlike RASSF1A, is a potential growth and
survival factor in breast cancer.
Identification of novel RASSF1C target genes
The observed increase in cell number in breast cancer
cells over-expressing RASSF1C predicted that over-
expression of RASSF1C might either down-regulate the
expression of cell growth inhibiting/pro-apoptotic genes
or up-regulate the expression of cell growth promoting/
anti-apoptotic genes. Affymetrix-microarray analysis was
performed using T47D cells over-expressing RASSF1C
to answer this question. The control sample was RNA
from T47D cells stably transduced with MLV-backbone
(T47D-BB) and the experimental sample was RNA from
T47D cells stably transduced with MLV-RASSF1C
(T47D-1C). Prior to RNA isolation, T47D-BB and
T47D-1C cells were treated with 1 μg/ml doxycycline
for 48 hr. Data analysis was performed using the dChip
program [21] and the thresholds for selecting significant
Figure 2 (A) Western blot analysis of Hs578T, MDA-MB231 and
T47D cells stably transduced with either empty MLV back
bone (BB) or MLV-HA-RASSF1C (1C) and treated with 1 μg/ml
doxycycline for 48 hr. The anti-HA tag antibody detected a HA-
RASSF1C fusion protein in cells transduced with 1C but not BB as
expected. (B) Hs578T, MDA-MB231, and T47D cells stably transduced
with an empty MLV-backbone (BB) or MLV-HA-RASSF1C (1C) vectors
were treated with 1 μg/ml doxycycline for 48 hr. Cells were
incubated with
3H-thymidine for 6 hr and
3H-thymidine
incorporation was assayed as previously described [19]. (C) Hs578T-
1C and T47D-1C treated with doxycycline showed an increase in
cell proliferation compared to cells not treated with doxycycline,
respectively. RASSF1C over-expression did not inhibit but rather
caused a small and statistically significant increase in cell
proliferation compared to cells stably transduced with empty MLV-
backbone vector. Values are mean ± SEM of 8 replicates;
experiments were performed at least three independent times.
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and 2-fold), absolute signal difference > = 50, and p <
0.05. Genes that met all three criteria were considered
as significant changes. Comparison results with False
Discovery Rate (FDR) <5% was considered as a valid
analysis.
We found that RASSF1C over-expression modulated
the expression of a number of genes that are involved
in cancer development, cell growth/proliferation, cell
cycle, cell death, and apoptosis (Table 2). RASSF1C
down-regulated several pro-apoptotic and tumor sup-
pressor genes, including Bcl2-associated protein (BAX)
[23], Caspase 3 [24], disabled homolog 2 (DAB2) [25],
epithelial membrane protein 1(EMP-1) [26], insulin-like
growth factor binding protein 3 (IGFBP-3) [27], mito-
chondrial tumor suppressor 1 (MTUSI) [28], ring finger
protein 182 (RFN182) [29], SRY (sex determining region
Y)-box 9 (SOX9) [30], sushi-repeat-containing protein,
X-linked (SPRX) [31], transglutaminase 2 (TGM2) [32],
and transmembrane protein 158 (TMEM158, also known
as Ras-induced senescence 1(Ris-1)) [33]. RASSF1C also
up-regulated several growth promoting genes that
include apolipoprotein E (APOE) [34], carboxypeptidase
E (CPE) [35], chemokine (C-X-C motif) receptor 4
(CXCR4) [36], human growth hormone receptor (GHR)
[37], homeobox A1 (HOXA1) [38], muscle RAS (MRAS)
oncogene homolog [39], SPANX family member A1
(SPANXA1), and SPANXB1 [40]. The RASSF1C target
genes identified in this study are consistent with a poten-
tial growth promoting role for RASSF1C in breast cancer
cells. We then selected several RASSF1C target genes
and confirmed the microarray results using RT-PCR ana-
lysis (Table 3). We also show that changes in mRNA
levels of caspase 3, CXCR4, GHR, and TGM2 are indeed
translated to a change in protein expression in T47D
cells (Figure 3A). We also found that T47D cell over-
expressing RASSF1C displayed higher levels of phos-
phorylated ERK1/2 compared to control cells (Figure
3B). It should be noted that total ERK1/2 levels were the
same in both T47D-BB and T47D-1C (Figure 3C). In
addition, we show that silencing of endogenous RASSF1C
expression in T47D cells resulted in an increase in cas-
pase 3 and a decrease in CXCR4 mRNA expression
(Table 4).
RASSF1C over-expression enhances breast cancer cells
invasion/migration in vitro
Because RASSF1C over-expression up-regulates the
expression of CXCR4, a key metastasis gene, we carried
out an in vitro invasion assay to determine if T47D cells
over-expressing RASSF1C and grown in the presence of
SDF-1 (the ligand for the CXCR4 receptor) were more
invasive than control cells. For the invasion assays,
T47D cells over-expressing RASSF1C were co-cultured
with the human stromal cell line Hs27a, which secretes
SDF-1, or were grown in conditioned serum-free med-
ium containing SDF-I. Figure 4A shows that T47D-1C
were significantly more invasive than the T47D-BB con-
trol cells. Interestingly, silencing of RASSF1C in T47D
cells using lentiviral shRNA transduction particles signif-
icantly reduces T47D cell invasion/migration compared
to cells infected with lentiviral shRNA control transduc-
tion particles (Figure 4B), further supporting that
RASSF1C may promote breast cancer cell invasion/
migration.
In addition to T47D cells, we also show that MDA-
MB231 cells over-expressing RASSF1C were more inva-
sive than the control cells (Figure 4C). All together, our
novel findings suggest that RASSF1C may promote
breast cancer cell invasion/migration perhaps in part
through the up-regulation of the expression of the
CXCR4 gene.
RASSF1C over-expression attenuates apoptotic sensitivity
in breast cancer cells
Etoposide is a chemotherapy agent that is known to
induce apoptosis through activation of caspase 3. Since
over-expression of RASSF1C down-regulates caspase 3
expression, we hypothesized that over-expression of
RASSF1C would reduce the amount of active caspase 3
that is induced by etoposide. We tested this hypothesis
by measuring the amount of caspase 3 produced in
response to etoposide by T47D breast cancer cells that
either over-express or normally express RASSF1C.
RASSF1C over-expressing cells (T47D-1C) exhibit
reduced caspase 3 activity compared to cells that do not
over-express RASSF1C (T47D-BB) when treated with
etoposide (Figure 5). To further show that prolonged
Table 1 RASSF1A and RASSF1C mRNA expression in
epithelial and breast cancer cell lines
Cell Line Gene Relative expression levels
AG1132B RASSF1A 1
RASSF1C 1
Hs578T RASSF1A -3.3
RASSF1C 4
MDA-MB231 RASSF1A -2.2
RASSF1C 7
T47D RASSF1A -8
RASSF1C 6
QRT-PCR analysis of total RNA from human primary mammary epithelial cells
(AG1132B) and from established breast cancer cell lines, Hs578T. MDA-MB231,
and T47D cells. 1 μg of total RNA was used to perform reverse transcription
reactions (RTs) and 1 ul of the RT reaction was used to set up qRT-PCR
reactions in triplicates using RASSF1A and RASSF1C specific primers. All qRT-
PCR reactions were set in triplicates and Cyclophillin was used as an internal
loading control and used to normalize the relative expression levels using the
2
-ΔΔ method [42]. The RT-PCR analysis shows that RASSF1A expression was
down and RASSF1C expression is up in established breast cancer cell lines
compared the primary mammary epithelial cells.
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Page 7 of 14over-expression of RASSF1C does not promote apopto-
sis in breast cancer cells, DNA fragmentation analysis
was carried out using genomic DNA isolated from
breast cancer cells treated with 1 μg/ml doxycycline for
14 days. Over-expression of RASSF1C did not induce
DNA fragmentation in breast cancer cells (Figure 6).
These findings further support our hypothesis that
RASSF1C plays a role in promoting breast cancer cell
growth, and it may allow cancer cells to evade killing by
chemotherapy agents.
Table 2 Novel RASSF1C target genes in T47D breast cancer cells
Gene Gene discription Fold change
EFEM1 EGF-containing fibulin-like extracellular matrix protein 1 5.76
GHR growth hormone receptor 4.3
EGR1 early growth response 1 5.9
TP53IN1 tumor protein p53 inducible nuclear protein 1 4.46
MRAS muscle RAS oncogene homolog 3.8
MTUS1 mitochondrial tumor suppressor 1 -2
PROS protein S (alpha) 4
EMP1 epithelial membrane protein 1 -7.5
HOXA1 homeobox A1 4.6
SEPP1 selenoprotein P, plasma, 1 7.92
MGMT O-6-methylguanine-DNA methyltransferase 2.1
PAK1 p21/Cdc42/Rac1-activated kinase 1 (STE20 homolog, yeast) 2.1
CXCR4 chemokine (C-X-C motif) receptor 4 3.6
CREG cellular repressor of E1A-stimulated genes 1 11.2
BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase) 2
Noggin Noggin -3.6
SSP1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1) -14.5
TGM2 TGM2: transglutaminase 2 (protein-glutamine-gamma-glutamyltransferase) 3
SRPX sushi-repeat-containing protein, X-linked -7.25
SAMD5 sterile alpha motif domain containing 5 -11.47
MAP1B microtubule-associated protein 1B -11.7
RNF182 ring finger protein 182 -13.8
TMEM8 transmembrane protein 158 -11.29
LDB2 LIM domain binding 2 -5.85
IGFBP3 insulin-like growth factor binding protein 3 -4.96
COL131 collagen, type XIII, alpha 1 -8.69
FRMDB FERM domain containing 4B -5.2
SOX9 SRY (sex determining region Y)-box 9 -4.5
DAB2 disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila) -2.55
APOE apolipoprotein E 3.74
CCND2 cyclin D2 -3
SPANX1 sperm protein associated with the nucleus, X-linked, family member A1 7.38
SPANX1 SPANX family, member B1 17.7
HLADP1 major histocompatibility complex, class II, DP alpha 1 12.7
HIST1H2BC histone cluster 1 H2BC 5.34
DACH1 dachshund homolog 1 (Drosophila) 7.63
PCDH7 protocadherin 7 8.58
MYL9 myosin, light chain 9, regulatory 9
DPEP3 dipeptidase 3 10.66
CPE carboxypeptidase E 11.47
LITAF lipopolysaccharide-induced TNF facto 8.17
ABAT 4-aminobutyrate aminotransferase 10.82
List of novel RASSF1C target genes identified in T47D breast cancer cells using microarray analysis. Affymetrix-microarray analysis was performed using T47D cells
over-expressing RASSF1C as outlined in Materials and Methods section. Data analysis was performed using the dChip program [21] and the thresholds for
selecting significant genes were set at a relative difference > = 1.5-fold (or/and 2-fold), absolute signal difference > = 50, and p < 0.05. Genes that met all three
criteria were considered as significant changes. Comparison results with False Discovery Rate (FDR) <5% was considered as a valid analysis.
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The function of RASSF1C has not been as extensively stu-
died as that of RASSF1A. Initial reports in the literature
suggested that RASSF1C might function as a tumor sup-
pressor in ovarian, prostate, renal cancer cells [15-17].
Recently, RASSF1C has been shown to interact with
DAXX, a protein involved in apoptosis and transcriptional
repression. It has been suggested that RASSF1C may con-
tribute to the activation of Stress-Activated Protein-
kinase/c-jun N-terminal kinase [17]. In contrast, we
recently demonstrated that RASSF1C promotes lung can-
cer cell proliferation [19]. We previously showed that
RASSF1C plays a role in promoting osteoblast cell prolif-
eration through interaction with Insulin like Growth Fac-
tor Binding protein (IGFBP)-5 [18]. Consistent with our
hypothesis, another group has recently shown that
RASSF1C interacts with bTrCP (the receptor subunit of
the SCF
bTrCP ubiquitin ligase that recruits signaling
proteins and cell cycle regulators for proteosomal degrada-
tion) [41]. Through this mechanism RASSF1C over-expres-
sion in the human lung cancer cell line A549 promotes the
accumulation b-catenin, an oncogene and a key player in
the Wnt signaling pathway, leading to increased transcrip-
tional activation and cell proliferation [41].
In this study, we demonstrated that reduction of
RASSF1C mRNA in breast cancer cells correlated with a
small but statistically significant decrease in cell prolifera-
tion compared to control cells that express RASSF1C.
The reduction in RASSF1C did not affect cell viability as
judged by trypan blue staining (data not shown). Overall
our results are consistent with those we obtained in
osteosarcoma (TE85, MG63, U2) and lung cancer (NCI
H1299) cells [18,19]. In the studies with osteosarcoma
cells, the effects of silencing RASSF1C in cells that
express both RASSF1A and RASSF1C (TE85) were very
similar to those observed in cells that express only
RASSF1C (MG63 and U2), clearly indicating that
RASSF1A does not modulate the effect of RASSF1C on
Table 3 Validation of selected RASSF1C target genes
Gene Fold Change
RASSF1C 252
Caspase 3 -3.3
CREG 4.9
CXCR4 5.4
EGR1 9.9
GHR 4.6
HOXA1 2.1
MRAS 4.8
List of selected RASSF1C target genes validated in the T47D breast cancer cell
line using RT-PCR. The RT-PCR reactions were carried out in triplicates and the
fold change was calculated using the 2
-ΔΔC
T method [22]. Cyclophyllin was
used as a loading control.
Table 4 Effects of silencing RASSF1C on target genes
Gene Fold change
RASSF1C -5
Caspase 3 +1.3
CXCR4 -2
Caspase3 and CXR4 gene expression in T47D cells treated with Mission®
lentiviral transduction particles specific to RASSF1C. The fold change is
compared to T47D cells treated control scrambled shRNA (Mission® lentiviral
transduction control particles). The RT-PCR reactions were carried out in
triplicate, and the fold change was calculated using the 2-ΔΔCT method [22].
Cyclophyllin was used as a loading control.
Figure 3 (A) Western blot analysis of caspase 3, CXCR4, GHR, and TGM2 expression in T47D cells stably transduced with empty MLV-
backbone (T47D-BB) or MLV-HA-RASSF1C (T47D-1C) using their corresponding antibodies. The T47D cells were treated with 1 μg/ml
doxycycline for 48 hr and used for Western blot analysis. It is clear that caspase 3 and TGM2 protein levels are down regulated and CXCR4 and
GHR are up regulated in T47D cells over expressing RASSF1C validating the microarray and qRT-PCR findings (Table 1 and 2). Activation of ERK1/
2 (B) and total ERK1/2 levels (C) were assessed in T47D-1C cells. The level of phosphorylated ERK1/2 in T47D-1C is much higher compared to
that in T47D-BB while the total ERK1/2 protein levels are relatively the same in T47D-BB and T47D-1C.
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Page 9 of 14Figure 4 (A) The BD BioCoatTM MatrigelTM Invasion Chamber was used to assess cell invasion/migration of T47D cells stably
transduced with empty MLV-backbone (T47D-BB) or MLV-HA-RASSF1C (T47D-1C). T47D-1C or T47D-BB cells treated with doxycycline at
1ug/ml were co-incubated with Hs27a human stromal cells. Hs27a cells express the stromal derived factor-1 (SDF-1), the ligand for the CXCR4
receptor. After 24 hr incubation period the lower sides of the filters were fixed and stained and cells in four microscopic fields were counted.
The average cell number count was plotted. T47D cells over-expression RASSF1C showed a higher number of cells invading the Matrigel
chamber and migrating to the other side of the filter compared to T47D-cells, p <0.003. (B) T47D-lenti-shRNA control (Mission, Sigma), T47D-
lenti-shRNA to silence RASSF1C (T47D-siRNA-1C) (Mission, Sigma), and T47D-1C cells were incubated with either non-conditioned serum-free
medium or SDF-1-conditioned serum-free medium for 24 hr. Lower number T47D-siRNA-1C cells invaded the Matrigel chamber and migrating to
the other side of the filter compared to T47D-siRNA control. (C) MDA-MB231-BB (MDA-BB) and MDA-MB231-1C (MDA-1C) cells were plated in
the chamber inserts and placed in wells containing either non-conditioned serum-free medium or SDF-1-conditioned serum-free medium, and
incubated for 24 hr. MDA-1C cells showed a higher number of cells invading the Matrigel chamber and migrating to the other side of the filter
compared to MDA-BB cells, p < 0.001. The data suggests a potential role for RASSF1C in cancer cell metastasis, perhaps through the up-
regulation of CXCR gene expression.
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Page 10 of 14cell proliferation and survival [18]. Based on these obser-
vations we think that, unlike RASSF1A, RASSF1C is not
a tumor suppressor at least in breast, bone, and lung.
Instead, it may function as a growth-stimulating factor.
To further determine the effect(s) of RASSF1C on breast
cancer cell proliferation, we used a tetracycline-regulated
MLV-based vector to stably over-express RASSF1C in
MDA-MB231 and T47D. Tetracycline-regulated over-
expression of RASSF1C did not inhibit cell proliferation.
In fact, over-expression of RASSF1C caused reproducible
and statistically significant increase in cell proliferation,
further suggesting that RASSF1C is not a growth suppres-
sor gene. In support of this, we have found that expression
of RASSF1C is elevated in breast cancer cell lines com-
pared to primary mammary epithelial cells, consistent with
our hypothesis that RASSF1C may act as a potential
growth and survival factor in breast cancer.
As mentioned above, a recent study suggested that
regulated over-expression of RASSF1C may inhibit the
growth of prostate cancer (LNCaP) and renal cell carci-
noma (KRC/Y) cells [15]. However, we have now shown
that RASSF1C over-expression does not inhibit cell
growth but rather significantly increases proliferation of
osteosarcoma [18], lung cancer [19], and breast cancer
(this study) cells. The different findings related to the
stimulatory function of RASSF1C in human osteosar-
coma, breast cancer, and lung cancer cells [18,19,21,41],
and the inhibitory function of RASSF1C in prostate, kid-
ney, and ovarian cancer cells [15-17] may be due to tis-
sue-specific actions of RASSF1C. It is well known that
some proteins such as IGFBP-5 and FHIT (Fragile Histi-
dine Triad) exert opposite effects in different tissues
[42,43]. Our silencing and over-expression studies of
RASSF1C underscores a potential growth promoting
function at least in breast, lung, and osteosarcoma cell
lines.
To begin to address the effect of RASSF1C on cellular
growth, we carried out a microarray study to identify
novel RASSF1C target genes. We found that RASSF1C
over-expression interestingly modulated the expression
of a number of genes that are involved in cancer
Figure 5 Caspase 3 activity was measured in T47D cells stably
transduced with MLV-HA-RASSF1C (T47D-RASSF1C). The T47D
cells treated with doxycycline (D) and/or 45 um/ml etoposide (E)
for 48 hr. Cells were subsequently assayed for caspase 3 activity.
RASSF1C over-expression down regulates the expression of caspase
3 and hence less caspase 3 activity is observed in T47D-1C cells
treated with both D and E compared to cells treated with E alone
(p < 0.01). Data normalized to T47D cells that were treated with
vehicle and the assay was carried at least three independent times
with N = 4.
Figure 6 T47D, MDA-MB231, and Hs578T cells stably
transduced with an empty MLV-backbone (T47D-, MDA-, and
Hs578T-BB) or MLV-HA-RASSF1C (T47D-, MDA-, and Hs578T-1C)
vectors were treated with 1 μg/ml doxycycline for 14 days.
Genomic DNA was isolated for DNA fragmentation analysis using
Apoptotic DNA ladder (ADL) kit. It is clear that DNA fragmentation
did not occur in all the three cell lines tested suggesting that
RASSF1C over-expression does not induce apoptosis.
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Page 11 of 14development, cell growth/proliferation, cell cycle, cell
death, and apoptosis. We validated the expression of sev-
eral RASSF1C target genes by QRT-PCR and have also
validated the expression of caspase 3, CXCR4, GHR, and
TGM2 by Western blot analysis. We also found that can-
cer cells over-expressing RASSF1C exhibited increased
phosphorylation of ERK1/2 compared to control cells (but
no increase in total ERK1/2 levels), suggesting that
RASSF1C may exert its activities in part through the acti-
vation of the ERK1/2 pathway. We also show that breast
cancer cells over-expressing RASSF1C showed enhanced
invasion/migration, while cells with knockdown of
RASSF1C expression had reduced invasion/migration
compared to control cells.
In addition, we found that RASSF1C over-expressing
cells exhibited reduced caspase 3 activity compared to
control cells when treated with etoposide. We also
found that over-expressing RASSF1C for 14 days did
not induce apoptosis as judged by lack of DNA frag-
mentation in Hs578T, MDA-MB231 and T47D cells,
further suggesting that RASSF1C does not promote
apoptosis. Taken together, the findings are consistent
with our hypothesis that RASSF1C may potentially func-
tion as a metastasis promoting and apoptosis attenuat-
ing protein in breast cancer cells perhaps through the
modulation of the CXCR4 and caspase 3 gene expres-
sion, respectively.
Our findings, together with others’, are building a case
that RASSF1C and RASSF1A have opposing, antagonistic
functions at least in breast, lung, and bone cancer cells.
For instance, it has been reported that RASSF1A inhibits
lung cancer cell migration and promotes cell adhesion
[44]. RASSF1A has also been shown to activate the pro-
apoptotic Bax1 gene [45] which is consistent with its
tumor suppressing activities. In this study, we have
shown that RASSF1C promotes cell migration and down-
regulates pro-apoptotic genes such as Bax, caspase 3, and
SRPX. RASSF1C over-expression also up-regulates the
expression of inhibitor of differentiation (Id2), which
has been shown to be down-regulated by RASSF1A in
nasopharyngeal carcinoma [46]. Also, RASSF1C down-
regulates TGM2 gene expression, which is up-regulated
by RASSF1A in the non-small cell lung cancer cell line
A549 [47]. Lastly, our RASSF1C studies in breast cancer,
lung cancer, and osteosarcoma cells, as well as other
reports in the literature [41] also suggest that RASSF1C
functions in an opposing manner to that of RASSF1A. In
all of these studies, RASSF1C appears to stimulate cell
growth, while RASSF1A is well established to suppress it.
Thus, a fine balance of RASSF1A and RASSF1C isoform
expression may be critical in determining the neoplastic
potential of a cell.
As mentioned above microarray analyses of mRNA
in cells subjected to forced expression of RASSF1C sti-
mulates expression and silencing of RASSF1C reduces
expression of genes that are associated with cell growth
and proliferation. These data provide significant infor-
mation to propose testable models to explain how
RASSF1C exerts it growth promoting activities in breast
cancer. For example, up-regulation of CXCR4 by
RASSF1C is an interesting discovery suggesting the
hypothesis that RASSF1C may play a role in promoting
breast cancer metastasis as mentioned above. Recent
studies have shown that CXCR4 expression is increased
early in the transition from normal to transformed
breast epithelium [48]. CXCR4 is a signaling receptor
that interacts with a cognate ligand (SDF-1, also known
as CXCL12) that is expressed at higher levels in tissues
that attract breast cancer cells and support metastasis
(e.g., bone, liver, lung). CXCR4 interaction with SDF-1
activates PI3K and Erk1/2 pathways and promotes can-
cer cell proliferation and metastasis [48,49]. In light of
these findings we are proposing a testable model of
RASSF1C action (see Figure 7) based on the hypothesis
that RASSF1C increases the expression of CXCR4 in
pre-malignant/malignant breast epithelial cells, thus sup-
porting successful seeding and metastases in sites that
express high levels of SDF-1. We plan to test this model
and others to delineate the molecular mechanism/path-
way(s) through which RASSF1C exerts its growth pro-
moting effects on breast cancer cells using both in vitro
and in vivo approaches.
In conclusion, together with our previous work on
RASSF1C in osteosarcoma and lung cancer cells, our pre-
sent findings in breast cancer cells provide further
Figure 7 A hypothetical model proposed to explain RASSF1C
action in breast cancer cells: we hypothesize that RASSF1C
activates the Ras-Raf-ERK1/2 pathway leading to up-regulation
of the CXCR4. Breast cancer cells expressing high number of CXCR4
receptor are attracted to migrate to secondary tissue sites where a
cognate ligand (CXCL12) is expressed at higher levels (e.g., bone,
liver, and lung).
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Page 12 of 14evidence that RASSF1C is not a tumor suppressor and
instead it may promote metastasis and survival of cancer
cells. Our studies further suggest that RASSF1C may
accomplish this by up-regulation of specific growth
promoting genes and down-regulation of specific pro-
apoptotic genes.
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